GSK vs HRB · P/E 13, $103.31B cap vs P/E 14, rev $3.95B
GlaxoSmithKline PLC ADR (GSK) versus H&R Block Inc (HRB) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
H&R Block Inc (HRB) is a personal services company listed on US.
GSK does not have a complete income-statement cache yet.
Latest reported HRB revenue for 2026-06-30 was $3.95B. Net income was $733.6M. Revenue was up 4.9% from 2025-06-30 to 2026-06-30. HRB currently screens at market cap $7.60B and trailing P/E 14.1.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. HRB currently screens at market cap $7.60B and trailing P/E 14.1.
Not investment advice. Open the GSK and HRB stock pages for the full models.
Not investment advice.